Understanding how a specific protein affects prostate cancer growth and treatment resistance
Official title: Mechanisms and vulnerabilities of ERG-driven luminal fate in prostate cancer
Funded at Research Inst of Fox Chase Can Ctr · NIH-11231970 · Data updated 2026-11-12
This study is looking at how a specific protein called ERG affects prostate cancer cells, especially those that are important for hormone treatments, to find new ways to make these cancer cells more vulnerable and improve treatment options for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | April 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $249,000 |
| NIH project number | 4R00CA276888-03 |
| Project ID | NIH-11231970 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are American men diagnosed with prostate cancer, especially those exhibiting luminal histology and resistance to hormone therapy.
✕Less likely to help
Patients with non-prostate cancers or those whose prostate cancer does not exhibit ERG overexpression may not benefit from this research.
What this research studies
This research investigates the role of the ERG oncoprotein in prostate cancer, particularly how it influences the behavior of luminal cells, which are a key target for hormone therapies. By using advanced mouse models and organoid systems, the study aims to uncover the molecular mechanisms that allow prostate cancer cells to invade and resist treatment. The research also employs genome-wide screening techniques to identify potential vulnerabilities in these cancer cells that could be targeted for new therapies. Insights gained from this work may lead to innovative treatment strategies for patients with prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with prostate cancer, particularly those who have developed resistance to current therapies.
How similar studies have gone: Previous research has shown promising results in targeting similar molecular pathways in cancer, suggesting that this approach may yield valuable insights and potential breakthroughs.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Feng, Weiran — Research Inst of Fox Chase Can Ctr
- Study coordinator: Feng, Weiran
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.